Wisevoter
U.S.

Helus Pharma Co-founders Resign From Executive Roles

The company appoints Mark Lawson as independent Chair of the Board of Directors following executive leadership changes.

Updated on Oct. 27, 2026 in People

Bold flat-color editorial illustration depicting stacked geometric volumes, symbolizing a formal corporate leadership transition and structural change.
Helus Pharma co-founders Eric So and Paul Glavine have resigned from executive roles, with board member Mark Lawson appointed as independent Chair. AI Illustration. Upload story photo >

Live Poll

Does high turnover in company leadership make you trust a business's long-term prospects less?

Helus Pharma co-founders Eric So and Paul Glavine have stepped down from their executive and consulting positions. The company has appointed board member Mark Lawson as the new independent Chair of the Board of Directors.

Why it matters

This leadership transition is intended to support the company as it moves into its next phase of corporate growth. The moves maintain continuity while signaling a shift in the company's internal management structure.

Mark Lawson brings 20 years of investment banking experience to his new role as independent Chair. He has been a member of the board since November 2020.

The players

Eric So

He is a co-founder of Helus Pharma who has transitioned to the role of Chairman Emeritus.

Paul Glavine

He is a co-founder of Helus Pharma who recently resigned from his executive and consulting roles.

Mark Lawson

He is an experienced investment banker who has been appointed as the independent Chair of the Helus Pharma Board.

Helus Pharma

This is a company with operations in New York and Toronto that is currently developing the HLP003 treatment.

The details

While Eric So and Paul Glavine have vacated their executive duties, both will remain on the Board of Directors. So has also been designated as Chairman Emeritus, and the company maintains offices in both New York and Toronto.

Timeline

  1. Mark Lawson joined the Board of Directors in November 2020.

  2. The co-founders resigned and the new Chair was appointed on October 27, 2026.

  3. The company plans to release Phase 3 study data in Q4 2026.

Market Landscape

The leadership change at Helus Pharma occurs as the company prepares to report topline data from the Phase 3 APPROACH study of HLP003 in late 2026. This transition aligns internal oversight with the critical clinical milestones required for the company's long-term growth.

This transition may influence investor sentiment as the company approaches key clinical trial results later this year. Shareholders should monitor official company communications for updates on the firm's strategic direction under the new leadership.

The takeaway

Leadership changes are a standard component of organizational maturation as firms move from founding stages toward large-scale clinical data releases. Investors often watch these transitions closely to gauge how a company intends to manage its research pipeline.

What happens next

Helus Pharma is scheduled to report topline data from the Phase 3 APPROACH study of HLP003 in the fourth quarter of 2026.

Further reading

For more on industry shifts, see People.

Source note: This article includes information reported by Financial Post.

Live Poll

Does high turnover in company leadership make you trust a business's long-term prospects less?